Silo Pharma Enters Agreement With CRO for Pharmacokinetic Study
Silo Pharma, Inc. recently announced it has entered into an agreement with Frontage Laboratories, a CRO providing integrated, science-driven, product development services throughout the drug discovery and development process that enable life science companies to achieve their drug development goals.
Frontage has worked with innovators and consumer health companies of all sizes to file IND, NDA, ANDA, BLA, and 505(b)(2) submissions in global markets allowing for the successful development of important patient therapies. The Pharmacokinetic Study in animals will be dose analyzed along with a full analysis of plasma samples.
Eric Weisblum, CEO of Silo Pharma, said “This agreement significantly advances our Central Nervous System Peptide, SPU-16, and our Joint Homing Peptide, SPU-21 technologies closer to the clinic. These solutions have the potential to enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic toxicity. These peptides also have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. They may be used to treat both Central Nervous System and Autoimmune Diseases.”
Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com.
Total Page Views: 768
